Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221114673
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction. Until recently, C5 inhibition with eculizumab or ravulizumab represented the only therapies approved… read more here.
Keywords: safety; nocturnal hemoglobinuria; pegcetacoplan; paroxysmal nocturnal ... See more keywords